3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
3
Neoplasms
3
Venous Thrombosis
2
Thromboembolism
2
Pulmonary Embolism
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
fludarabine phosphate
58
Cyclophosphamide
54
Peripheral Blood Stem Cell Transplantation
49
Mycophenolic Acid
39
Busulfan
38
Tacrolimus
37
Cyclosporine
33
Antilymphocyte Serum
33
Whole-Body Irradiation
32
Filgrastim
28
Methotrexate
27
Radiotherapy
20
Melphalan
18
Cytarabine
17
fludarabine
16
Etoposide
16
Methylprednisolone
14
ruxolitinib
11
sargramostim
9
Flow Cytometry
9
Cyclosporins
9
Cord Blood Stem Cell Transplantation
9
Alemtuzumab
9
thymoglobulin
8
Sirolimus
8
Psychiatric Rehabilitation
8
Granulocyte Colony-Stimulating Factor
8
Azacitidine
8
merphos
7
Decitabine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Myeloproliferative Disorders
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled